Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Oncopeptides AB's share price for the quarter that ended in Mar. 2026 was €0.1246. Oncopeptides AB's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 381.15 Mil. Therefore, Oncopeptides AB's market cap for the quarter that ended in Mar. 2026 was €47.49 Mil.
Oncopeptides AB's quarterly market cap
declined
from Sep. 2025 (€115.49 Mil) to Dec. 2025 (€114.50 Mil) and
declined
from Dec. 2025 (€114.50 Mil) to Mar. 2026 (€47.49 Mil).
Oncopeptides AB's annual market cap
declined
from Dec. 2023 (€63.03 Mil) to Dec. 2024 (€27.65 Mil) but then
increased
from Dec. 2024 (€27.65 Mil) to Dec. 2025 (€114.50 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Oncopeptides AB's Enterprise Value for Today is €49.90 Mil.
Oncopeptides AB (FRA:OND) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Oncopeptides AB Market Cap Related Terms
Oncopeptides AB Market Cap Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OND vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Oncopeptides AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Oncopeptides AB's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncopeptides AB (FRA:OND) has a Market Cap of €56.61 Mil as of Jun. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Oncopeptides AB and its competitors. According to the industry distribution chart, Oncopeptides AB ranks #845 out of 1431 companies in the Biotechnology industry, placing it in the top 59%.
Is Oncopeptides AB's Market Cap too high?
Oncopeptides AB's current Market Cap is €56.61 Mil. Based on the distribution chart, Oncopeptides AB ranks #845 out of 1431 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oncopeptides AB has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #845 out of 1431 companies for Market Cap. This places Oncopeptides AB in the lower half of its industry. The industry median Market Cap is 113.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current Market Cap is €56.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.14 — trading 61.6% below its estimated fair value. The current Market Cap is €56.61 Mil. Oncopeptides AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current Market Cap is €56.61 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 61.6% below its estimated GF Value™ of €0.37.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
Market Cap: €56.61 Mil
GF Value™: €0.37 vs. price of €0.14 (61.6% below fair value)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
30GF Score
Get the complete analysis for FRA:OND
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
